Sees FY24 revenue of $1.83B-$1.93B, consensus $2.06B. The company also announced the appointment of two new board members, Mary Beckerle and Gail Eckhardt. Board of Directors authorized $450M share repurchase in 2024 after successful completion of $550M share repurchase in 2023.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EXEL:
- Exelixis initiated with a Buy at BTIG
- Exelixis initiated with bullish view at Citi, here’s why
- Exelixis initiated with a Buy at Citi
- Exelixis, Arcus team on trial of zanzalintinib-AB521 combo to treat ccRCC
- Exelixis initiates STELLAR-305 trial evaluating zanzalintinib combo for SCCHN
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue